Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 84

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa

Daikos, George L., da Cunha, Clóvis Arns, Rossolini, Gian Maria, Stone, Gregory G., Baillon-Plot, Nathalie, Tawadrous, Margaret, Irani, Paurus · 2021 · Antibiotics

Abstract

Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) phenotypes. Ceftazidime–avibactam is a combination antimicrobial agent comprising ceftazidime, a third-generation semisynthetic cephalosporin, and avibactam, a novel non-β-lactam β-lactamase inhibitor. This review explores the potential role of ceftazidime–avibactam for the treatment of P. aeruginosa infections. Ceftazidime–avibactam has good in vitro activity against P. aeruginosa relative to comparator β-lactam agents and fluoroquinolones, comparable to amikacin and ceftolozane–tazobactam. In Phase 3 clinical trials, ceftazidime–avibactam has generally demonstrated similar clinical and microbiological outcomes to comparators in patients with complicated intra-abdominal infections, complicated urinary tract infections or hospital-acquired/ventilator-associated pneumonia caused by P. aeruginosa. Although real-world data are limited, favourable outcomes with ceftazidime–avibactam treatment have been reported in some patients with MDR and XDR P. aeruginosa infections. Thus, ceftazidime–avibactam may have a potentially important role in the management of serious and complicated P. aeruginosa infections, including those caused by MDR and XDR strains.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/antibiotics10091126

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 121

  1. Rhodes, 2018, Resistance trends and treatment options in Gram-negative ventilator-associated pneumonia, Curr. Infect. Dis. Rep., 20, 3, 10.1007/s11908-018-0609-x · DOI
  2. Liu, 2016, Point-prevalence survey of healthcare-associated infections in Beijing, China: A survey and analysis in 2014, J. Hosp. Infect., 93, 271, 10.1016/j.jhin.2016.03.019 · DOI
  3. Sadikot, 2005, Pathogen-host interactions in Pseudomonas aeruginosa pneumonia, Am. J. Respir. Crit. Care Med., 171, 1209, 10.1164/rccm.200408-1044SO · DOI · Paper page
  4. Markou, 2014, Pathogenesis of intestinal Pseudomonas aeruginosa infection in patients with cancer, Front. Cell. Infect. Microbiol., 3, 115, 10.3389/fcimb.2013.00115 · DOI
  5. Finnan, 2004, Genome diversity of Pseudomonas aeruginosa isolates from cystic fibrosis patients and the hospital environment, J. Clin. Microbiol., 42, 5783, 10.1128/JCM.42.12.5783-5792.2004 · DOI · Paper page
  6. Tummler, 2019, Emerging therapies against infections with Pseudomonas aeruginosa, F1000Res., 8, F1000 Faculty Rev-1371, 10.12688/f1000research.19509.1 · DOI
  7. Babich, 2019, Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: A retrospective multicentre study, Int. J. Antimicrob. Agents, 55, 105847, 10.1016/j.ijantimicag.2019.11.004 · DOI
  8. Ippolito, M., Misseri, G., Catalisano, G., Marino, C., Ingoglia, G., Alessi, M., Consiglio, E., Gregoretti, C., Giarratano, A., and Cortegiani, A. (2021). Ventilator-associated pneumonia in patients with covid-19: A systematic review and meta-analysis. Antibiotics, 10. · DOI
  9. Horcajada, 2019, Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections, Clin. Microbiol. Rev., 32, e00031-19, 10.1128/CMR.00031-19 · DOI · Paper page
  10. Moradali, 2017, Pseudomonas aeruginosa lifestyle: A paradigm for adaptation, survival, and persistence, Front. Cel.l Infect. Microbiol., 7, 39
  11. Mulcahy, 2014, Pseudomonas aeruginosa biofilms in disease, Microb. Ecol., 68, 1, 10.1007/s00248-013-0297-x · DOI · Paper page
  12. Carmeli, 1999, Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents, Antimicrob. Agents Chemother., 43, 1379, 10.1128/AAC.43.6.1379 · doi:10.1128/aac.43.6.1379
  13. Yusuf, 2017, Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: Association with the duration of antibiotic exposure and mode of administration, Ann. Intensive Care, 7, 1, 10.1186/s13613-017-0296-z · DOI
  14. Feng, 2016, Dynamics of mutations during development of resistance by Pseudomonas aeruginosa against five antibiotics, Antimicrob. Agents Chemother., 60, 4229, 10.1128/AAC.00434-16 · DOI
  15. Yayan, J., Ghebremedhin, B., and Rasche, K. (2015). Antibiotic resistance of Pseudomonas aeruginosa in pneumonia at a single university hospital center in Germany over a 10-year period. PLoS ONE, 10. · DOI · Paper page
  16. Canton, 2020, Antimicrobial resistance in ICUs: An update in the light of the COVID-19 pandemic, Curr. Opin. Crit. Care, 26, 433, 10.1097/MCC.0000000000000755 · DOI
  17. Miranda, 2020, Implications of antibiotics use during the COVID-19 pandemic: Present and future, J. Antimicrob. Chemother., 75, 3413, 10.1093/jac/dkaa350 · doi:10.1093/jac/dkaa350
  18. Bassetti, M., Vena, A., Sepulcri, C., Giacobbe, D.R., and Peghin, M. (2020). Treatment of bloodstream infections due to Gram-negative bacteria with difficult-to-treat resistance. Antibiotics., 9. · DOI
  19. Kadri, 2018, National Institutes of Health Antimicrobial Resistance Outcomes Research, I. Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents, Clin. Infect. Dis., 67, 1803
  20. Strich, 2020, Needs assessment for novel Gram-negative antibiotics in US hospitals: A retrospective cohort study, Lancet Infect. Dis., 20, 1172, 10.1016/S1473-3099(20)30153-5 · DOI
  21. Pang, 2019, Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies, Biotechnol. Adv., 37, 177, 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
  22. Zhanel, 2013, Ceftazidime-avibactam: A novel cephalosporin/beta-lactamase inhibitor combination, Drugs, 73, 159, 10.1007/s40265-013-0013-7 · DOI · Paper page
  23. Shirley, 2018, Ceftazidime-avibactam: A review in the treatment of serious Gram-negative bacterial infections, Drugs, 78, 675, 10.1007/s40265-018-0902-x · DOI · Paper page
  24. Falcone, 2016, Spotlight on ceftazidime/avibactam: A new option for MDR Gram-negative infections, J. Antimicrob. Chemother., 71, 2713, 10.1093/jac/dkw239 · DOI · Paper page
  25. Falcone, 2021, Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients, J. Antimicrob. Chemother., 76, 1025, 10.1093/jac/dkaa549 · DOI
  26. Rains, 1995, Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy, Drugs, 49, 577, 10.2165/00003495-199549040-00008 · doi:10.2165/00003495-199549040-00008
  27. Walkty, 2014, Ceftazidime-avibactam: An evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections, Core Evid., 9, 13
  28. Stone, 2020, In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015 to 2017, Int. J. Antimicrob. Agents, 56, 106045, 10.1016/j.ijantimicag.2020.106045 · DOI
  29. Sader, 2018, Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. Census Divisions: Results from the 2017 INFORM Program, Antimicrob. Agents Chemother., 62, e01587-18, 10.1128/AAC.01587-18 · DOI
  30. Sader, 2017, Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the international network for optimal resistance monitoring program in the United States, Antimicrob. Agents Chemother., 61, e02252-16, 10.1128/AAC.02252-16 · DOI
  31. Huband, 2016, In vitro activity of ceftazidime-avibactam against contemporary pseudomonas aeruginosa isolates from U.S. medical centers by census region, 2014, Antimicrob. Agents Chemother., 60, 2537, 10.1128/AAC.03056-15 · DOI
  32. Mah, 2003, A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance, Nature, 426, 306, 10.1038/nature02122 · DOI · Paper page
  33. Kung, 2010, The accessory genome of Pseudomonas aeruginosa, Microbiol. Mol. Biol. Rev., 74, 621, 10.1128/MMBR.00027-10 · DOI · Paper page
  34. Cabot, 2018, The versatile mutational resistome of Pseudomonas aeruginosa, Front. Microbiol., 9, 685, 10.3389/fmicb.2018.00685 · DOI · Paper page
  35. Lister, 2009, Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms, Clin. Microbiol. Rev., 22, 582, 10.1128/CMR.00040-09 · DOI · Paper page
  36. Botelho, 2019, Antibiotic resistance in Pseudomonas aeruginosa—mechanisms, epidemiology and evolution, Drug Resist. Updat., 44, 100640, 10.1016/j.drup.2019.07.002 · DOI · Paper page
  37. Rossolini, 2005, Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa, Clin. Microbiol. Infect., 11, 17, 10.1111/j.1469-0691.2005.01161.x · DOI · Paper page
  38. Breidenstein, 2011, Pseudomonas aeruginosa: All roads lead to resistance, Trends Microbiol., 19, 419, 10.1016/j.tim.2011.04.005 · DOI · Paper page
  39. Wolter, 2013, Mechanisms of β-lactam resistance among Pseudomonas aeruginosa, Curr. Pharm. Design., 19, 209, 10.2174/138161213804070311 · DOI
  40. Eichenberger, E.M., and Thaden, J.T. (2019). Epidemiology and mechanisms of resistance of extensively drug resistant gram-negative bacteria. Antibiotics, 8. · DOI · Paper page
  41. Zamorano, 2019, Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology, J. Antimicrob. Chemother., 74, 1825, 10.1093/jac/dkz147 · DOI
  42. Potron, 2015, Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology, Int. J. Antimicrob. Agents, 45, 568, 10.1016/j.ijantimicag.2015.03.001 · DOI · Paper page
  43. Poirel, 2001, Characterization of Class 1 integrons from Pseudomonas aeruginosa that contain the bla(VIM-2) carbapenem-hydrolyzing beta-lactamase gene and of two novel aminoglycoside resistance gene cassettes, Antimicrob. Agents Chemother., 45, 546, 10.1128/AAC.45.2.546-552.2001 · doi:10.1128/aac.45.2.546-552.2001
  44. Yan, 2006, Characterization of acquired beta-lactamases and their genetic support in multidrug-resistant Pseudomonas aeruginosa isolates in Taiwan: The prevalence of unusual integrons, J. Antimicrob. Chemother., 58, 530, 10.1093/jac/dkl266 · doi:10.1093/jac/dkl266
  45. Maurice, 2018, Pseudomonas aeruginosa biofilms: Host response and clinical implications in lung infections, Am. J. Respir. Cell Mol. Biol., 58, 428, 10.1165/rcmb.2017-0321TR · DOI · Paper page
  46. Juan, 2017, Diversity and regulation of intrinsic beta-lactamases from non-fermenting and other Gram-negative opportunistic pathogens, FEMS Microbiol. Rev., 41, 781, 10.1093/femsre/fux043 · DOI
  47. Berrazeg, 2015, Mutations in beta-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins, Antimicrob. Agents Chemother., 59, 6248, 10.1128/AAC.00825-15 · DOI · Paper page
  48. Lodge, 1991, The control of class I beta-lactamase expression in Enterobacteriaceae and Pseudomonas aeruginosa, J. Antimicrob. Chemother., 28, 167, 10.1093/jac/28.2.167 · doi:10.1093/jac/28.2.167
  49. Bagge, 2002, Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD, Antimicrob. Agents Chemother., 46, 3406, 10.1128/AAC.46.11.3406-3411.2002 · DOI
  50. Zhang, 2010, ampG gene of Pseudomonas aeruginosa and its role in beta-lactamase expression, Antimicrob. Agents Chemother., 54, 4772, 10.1128/AAC.00009-10 · doi:10.1128/aac.00009-10
  51. Yin, 2018, Molecular typing and carbapenem resistance mechanisms of Pseudomonas aeruginosa isolated from a Chinese burn center from 2011 to 2016, Front. Microbiol., 9, 1135, 10.3389/fmicb.2018.01135 · DOI
  52. Li, 2012, Structure and function of OprD protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies, Int. J. Med. Microbiol., 302, 63, 10.1016/j.ijmm.2011.10.001 · DOI · Paper page
  53. Dou, 2017, Pseudomonas aeruginosa prevalence, antibiotic resistance and antimicrobial use in Chinese burn wards from 2007 to 2014, J. Int. Med. Res., 45, 1124, 10.1177/0300060517703573 · doi:10.1177/0300060517703573
  54. Hawkey, 2018, Treatment of infections caused by multidrug-resistant Gram-negative bacteria: Report of the British society for antimicrobial chemotherapy/healthcare infection society/british infection association joint working party, J. Antimicrob. Chemother., 73, iii2, 10.1093/jac/dky027 · DOI · Paper page
  55. Mensa, 2018, Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish society of chemotherapy, Rev. Esp. Quimioter., 31, 78
  56. Sartelli, 2017, The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections, World J. Emerg. Surg., 12, 29, 10.1186/s13017-017-0141-6 · DOI · Paper page
  57. Mazuski, 2017, The surgical infection society revised guidelines on the management of intra-abdominal infection, Surg. Infect., 18, 1, 10.1089/sur.2016.261 · DOI · Paper page
  58. Kalil, 2016, Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society, Clin. Infect. Dis., 63, e61, 10.1093/cid/ciw353 · DOI · Paper page
  59. Castellani, 2018, ECFS best practice guidelines: The 2018 revision, J. Cyst. Fibros., 17, 153, 10.1016/j.jcf.2018.02.006 · DOI · Paper page
  60. Solomkin, 2010, Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America, Clin. Infect. Dis., 50, 133, 10.1086/649554 · DOI · Paper page
  61. Parkins, 2018, Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis, Clin. Microbiol. Rev., 31, e00019–18, 10.1128/CMR.00019-18 · DOI · Paper page
  62. Watanabe, 1996, Newer antipseudomonal cephalosporins, J. Chemother., 8, 48
  63. Zhanel, 2014, Ceftolozane/tazobactam: A novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli, Drugs, 74, 31, 10.1007/s40265-013-0168-2 · DOI · Paper page
  64. Mushtaq, 2010, In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters, J. Antimicrob. Chemother., 65, 2376, 10.1093/jac/dkq306 · DOI
  65. Abboud, 2016, Interaction of avibactam with class B metallo-beta-lactamases, Antimicrob. Agents Chemother., 60, 5655, 10.1128/AAC.00897-16 · DOI
  66. Buehrle, 2016, Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates, Antimicrob. Agents Chemother., 60, 3227, 10.1128/AAC.02969-15 · DOI
  67. Sader, 2017, Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant enterobacteriaceae and pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016, Antimicrob. Agents Chemother., 61, e01045-17, 10.1128/AAC.01045-17 · DOI
  68. Lahiri, 2015, Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC, J. Antimicrob. Chemother., 70, 1650, 10.1093/jac/dkv004 · DOI
  69. Xu, 2020, Mechanisms for rapid evolution of carbapenem resistance in a clinical isolate of pseudomonas aeruginosa, Front. Microbiol., 11, 1390, 10.3389/fmicb.2020.01390 · doi:10.3389/fmicb.2020.01390
  70. Zamudio, 2019, Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients, Int. J. Antimicrob. Agents, 53, 774, 10.1016/j.ijantimicag.2019.02.022 · DOI
  71. Cabot, 2018, Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa, J. Antimicrob. Chemother., 73, 658, 10.1093/jac/dkx424 · DOI · Paper page
  72. Chen, 2021, In vitro activity of ceftazidime-avibactam alone and in combination with amikacin against colistin-resistant gram-negative pathogens, Microb. Drug Resist., 27, 401, 10.1089/mdr.2019.0463 · doi:10.1089/mdr.2019.0463
  73. Mikhail, 2019, Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 63, e00779-19, 10.1128/AAC.00779-19 · DOI · Paper page
  74. Yilmaz, 2020, Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of Pseudomonas aeruginosa, Infect. Dis., 52, 616, 10.1080/23744235.2020.1767803 · DOI
  75. (2020, December 04). Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition. CLSI Supplement M100. Available online: http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI%20M100%20ED30:2020.
  76. Nichols, 2016, In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014), Antimicrob. Agents Chemother., 60, 4743, 10.1128/AAC.00220-16 · DOI · Paper page
  77. Kazmierczak, 2016, Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam, Antimicrob. Agents Chemother., 60, 4490, 10.1128/AAC.00107-16 · DOI
  78. Sader, 2017, Antimicrobial activity of ceftazidime-avibactam against Gram-negative bacteria isolated from patients hospitalized with pneumonia in U.S. medical centers, 2011 to 2015, Antimicrob. Agents Chemother., 61, e02083-16, 10.1128/AAC.02083-16 · DOI
  79. Atkin, 2018, Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam, Infect. Drug Resist., 11, 1499, 10.2147/IDR.S173804 · DOI
  80. Sader, 2019, Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018), Diagn. Microbiol. Infect. Dis., 96, 114833, 10.1016/j.diagmicrobio.2019.05.005 · DOI
  81. Hassan, 2019, Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar, J. Antimicrob. Chemother., 74, 3497, 10.1093/jac/dkz379 · DOI
  82. Humphries, 2017, Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates, Antimicrob. Agents Chemother., 61, e01858-17, 10.1128/AAC.01858-17 · doi:10.1128/aac.01858-17
  83. Conejo, 2020, Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia, J. Antimicrob. Chemother., 75, 1840, 10.1093/jac/dkaa117 · DOI
  84. Zamorano, 2020, Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants, Antimicrob. Agents Chemother., 64, e02165-19, 10.1128/AAC.02165-19 · DOI
  85. Karlowsky, 2020, In vitro activity of WCK 5222 (Cefepime-zidebactam) against worldwide collected gram-negative bacilli not susceptible to carbapenems, Antimicrob. Agents Chemother., 64, e01432-20, 10.1128/AAC.01432-20 · DOI
  86. Nichols, 2018, Avibactam pharmacokinetic/pharmacodynamic targets, Antimicrob. Agents Chemother., 62, e02446-17, 10.1128/AAC.02446-17 · doi:10.1128/aac.02446-17
  87. Li, 2019, Ceftazidime-avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups, Clin. Transl. Sci., 12, 151, 10.1111/cts.12585 · DOI
  88. Das, 2019, Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia, Antimicrob. Agents Chemother., 63, e02187-18, 10.1128/AAC.02187-18 · DOI
  89. Nichols, 2018, Ceftazidime-avibactam susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 62, e02590-17, 10.1128/AAC.02590-17 · doi:10.1128/aac.02590-17
  90. Berkhout, 2016, Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection, Antimicrob. Agents Chemother., 60, 368, 10.1128/AAC.01269-15 · doi:10.1128/aac.01269-15
  91. Coleman, 2014, Activities of ceftazidime and avibactam against beta-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model, Antimicrob. Agents Chemother., 58, 3366, 10.1128/AAC.00080-14 · doi:10.1128/aac.00080-14
  92. Housman, 2014, Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model, Antimicrob. Agents Chemother., 58, 1365, 10.1128/AAC.02161-13 · DOI
  93. Dimelow, 2018, Population pharmacokinetic modelling of ceftazidime and avibactam in the plasma and epithelial lining fluid of healthy volunteers, Drugs R. D., 18, 221, 10.1007/s40268-018-0241-0 · doi:10.1007/s40268-018-0241-0
  94. Berkhout, 2015, Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice, Antimicrob. Agents Chemother., 59, 2299, 10.1128/AAC.04627-14 · DOI
  95. Lucasti, 2013, Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: Results of a randomized, double-blind, Phase II trial, J. Antimicrob. Chemother., 68, 1183, 10.1093/jac/dks523 · DOI · Paper page
  96. Vazquez, 2012, Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: Results of a prospective, investigator-blinded, randomized study, Curr. Med. Res. Opin., 28, 1921, 10.1185/03007995.2012.748653 · DOI · Paper page
  97. Mazuski, 2016, Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized, controlled, double-blind, phase 3 program, Clin. Infect. Dis., 62, 1380, 10.1093/cid/ciw133 · DOI · Paper page
  98. Carmeli, 2016, Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): A randomised, pathogen-directed, phase 3 study, Lancet Infect. Dis., 16, 661, 10.1016/S1473-3099(16)30004-4 · DOI · Paper page
  99. Qin, 2017, A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia, Int. J. Antimicrob. Agents, 49, 579, 10.1016/j.ijantimicag.2017.01.010 · doi:10.1016/j.ijantimicag.2017.01.010
  100. Wagenlehner, 2016, Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program, Clin. Infect. Dis., 63, 754, 10.1093/cid/ciw378 · DOI · Paper page
  101. Torres, 2018, Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): A randomised, double-blind, phase 3 non-inferiority trial, Lancet Infect. Dis., 18, 285, 10.1016/S1473-3099(17)30747-8 · DOI · Paper page
  102. Stone, 2018, Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: Pooled data from the ceftazidime/avibactam Phase III clinical trial programme, J. Antimicrob. Chemother., 73, 2519, 10.1093/jac/dky204 · DOI
  103. Mazuski, J., Wagenlehner, F., Torres, A., Carmeli, Y., Chow, J.W., Wajsbrot, D., Stone, G.G., Irani, P., Bharucha, D., and Cheng, K. (2021). Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. Infect. Dis. Ther., in press. · DOI
  104. Soriano, A., Carmeli, Y., Omrani, A.S., Moore, L.S.P., Tawadrous, M., and Irani, P. (2021). Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. Infect. Dis. Ther., 1–46. · DOI
  105. Algwizani, 2018, Experience with ceftazidime-avibactam treatment in a tertiary care center in Saudi Arabia, J. Infect. Public Health, 11, 793, 10.1016/j.jiph.2018.04.013 · doi:10.1016/j.jiph.2018.04.013
  106. Gofman, 2018, Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin, Am. J. Health Syst. Pharm., 75, 953, 10.2146/ajhp170632 · DOI
  107. Jorgensen, 2019, Real-world experience with ceftazidime-avibactam for multidrug-resistant Gram-negative bacterial infections, Open Forum Infectious Diseases, Volume 6, ofz522, 10.1093/ofid/ofz522 · DOI
  108. King, M., Huang, V., Gallagher, J., and Heil, E. (2016). Outcomes with ceftazidime/avibactam in patients with carbapenem-resistant pseudomonas infections: A multi-center study. Open Forum Infectious Diseases, Oxford University Press. · doi:10.1093/ofid/ofw172.1582
  109. Kuang, 2020, Clinical characteristics and outcomes of patients with multidrug-resistant Gram-negative bacterial infections treated with ceftazidime/avibactam, J. Glob. Antimicrob. Resist., 23, 404, 10.1016/j.jgar.2020.10.023 · doi:10.1016/j.jgar.2020.10.023
  110. Meschiari, 2020, Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: Three cases and a review of the literature, Infection, 49, 549, 10.1007/s15010-020-01539-9 · DOI
  111. Metafuni, 2019, Ceftazidime-avibactam for Gram-negative multidrug-resistant bacteria in hematological patients: A single-center experience, Ann. Hematol., 98, 1495, 10.1007/s00277-018-3535-y · doi:10.1007/s00277-018-3535-y
  112. Ripa, 2018, Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa, J. Glob. Antimicrob. Resist., 15, 136, 10.1016/j.jgar.2018.07.010 · DOI
  113. Santevecchi, 2018, Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae, Int. J. Antimicrob. Agents, 51, 629, 10.1016/j.ijantimicag.2018.01.016 · DOI
  114. Spoletini, 2019, Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: A case series, J. Antimicrob Chemother., 74, 1425, 10.1093/jac/dky558 · DOI
  115. Vena, A., Giacobbe, D.R., Castaldo, N., Cattelan, A., Mussini, C., Luzzati, R., Rosa, F.G., Puente, F.D., Mastroianni, C.M., and Cascio, A. (2020). Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant Gram-negative bacteria other than carbapenem-resistant Enterobacterales. Antibiotics, 9. · DOI
  116. Xipell, 2017, Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa, Int. J. Antimicrob. Agents, 49, 266, 10.1016/j.ijantimicag.2016.11.005 · doi:10.1016/j.ijantimicag.2016.11.005
  117. Temkin, 2017, Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms, Antimicrob. Agents Chemother., 61, e01964-16, 10.1128/AAC.01964-16 · doi:10.1128/aac.01964-16
  118. Nwankwo, 2021, Experience of Ceftazidime/avibactam in a UK tertiary cardiopulmonary specialist center, Expert Rev. Anti-Infect. Ther., 19, 101, 10.1080/14787210.2020.1810568 · doi:10.1080/14787210.2020.1810568
  119. Chen, 2020, Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli, Ann. Transl. Med., 8, 39, 10.21037/atm.2019.10.40 · DOI
  120. Morata, 2012, Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia, Antimicrob. Agents Chemother., 56, 4833, 10.1128/AAC.00750-12 · DOI · Paper page
  121. Gudiol, 2020, Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance, Clin. Infect. Dis., 70, 1068

Cited by

See all 84

Metadata

Authors
Daikos, G. L., da Cunha, C. A., Rossolini, G. M., Stone, G. G., Baillon-Plot, N., Tawadrous, M., & Irani, P.
Affiliations
  • Department of Medicine, National and Kapodistrian University of Athens, 115-27 Athens, Greece
  • Hospital Nossa Senhora das Graças, Curitiba 80810-040, PR, Brazil
  • Department of Experimental and Clinical Medicine, University of Florence, I-50134 Florence, Italy
  • Pfizer, Groton, CT 06340, USA
  • Pfizer, CEDEX 14, 75688 Paris, France
  • Pfizer, Tadworth, Surrey KT20 7NS, UK
Venue
Antibiotics
Publisher
MDPI AG
Published
2021-09-18
Volume
10
Issue
9
Pages
1126
ISSN
2079-6382
Cited by
84
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa. https://app.cochat.ai/papers/10.3390/antibiotics10091126
The paper
Daikos, G. L., da Cunha, C. A., Rossolini, G. M., Stone, G. G., Baillon-Plot, N., Tawadrous, M., & Irani, P. (2021). Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa. Antibiotics. https://doi.org/10.3390/antibiotics10091126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.